Allosteric Agonist Modulators

REFERENCES

• Schwartz T W, Holst B. Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J Receptors Signal Trans 2006; 26(1–2)107–128
   Web of Science ®Google Scholar
• Ehlert F J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 1988; 33: 187–194
   PubMed Web of Science ®Google Scholar
• Black J W, Leff P. Operational models of pharmacological agonist. Proc Roy Soc Lond [Biol] 1983; 220: 141–162
   PubMed Web of Science ®Google Scholar
• Bartus R T, Dean R L, Beer B, Lippa A S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408–414
   PubMed Web of Science ®Google Scholar
• Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque E X. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 2000; 11: 199–206
   Google Scholar
• Rogers S L, Farlow M R, et al. The Donepezil Study Group. Neurology 1998; 50: 136
   PubMed Web of Science ®Google Scholar
• Maelicke A. Albuquerque EX. New approach to drug therapy in Alzheimer's dementia. Drug Discovery Today 1996; 1: 53–59
   Web of Science ®Google Scholar
• Krause R M, Buisson B, Bertrand S, Corringer P-J, Galzi J-L, Changeux J-P, Bertrand D. Ivermectin: A positive allosteric effector of the 7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 1998; 53: 283–294
   PubMed Web of Science ®Google Scholar
• May L T, Leach K. et al. Allosteric modulation of G protein-coupled receptors Ann Rev Pharmacol Toxicol 2007; 47: 1–51
   PubMedGoogle Scholar
• Rees S, Morrow D, Kenakin T. GPCR drug discovery through the exploitation of allosteric drug binding sites. Receptors Channels 2002; 8: 261–268
   PubMedGoogle Scholar
• Holst B, Elling C E, Schwartz T W. Metal-ion mediated agonism and agonist enhancement in the melanocortin MC1 and MC4 receptors. J Biol Chem 2002; 277: 47662–47670
   PubMed Web of Science ®Google Scholar
• Bruns R F, Fergus J H. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 1990; 38: 939–949
   PubMed Web of Science ®Google Scholar
• Binet V, Brajon C, Le Corre L, Archer F, Pin J-P, Prezeau L. The heptahelical domain of GABAB2 is activated directly by CGP7930, a positive modulator of the GABAB receptor. J Biol Chem 2004; 279: 29085–29091
   PubMed Web of Science ®Google Scholar
• Urwyler S, Mosbacher J, Lingenhoehl K, Heid J, Hostetter Km Froestl W, Bettler B, Kaupmann K. Positive allosteric modulation of native and recombinant gamma-aminobutyric acidB receptors by 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol (CGP7930) and its aldehyde analog CGP13501. Mol Pharmacol 2001; 60: 963–971
   PubMedGoogle Scholar
• Langmead C J, Victoria A H, et al. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic m1 receptor: Direct pharmacological evidence that AC-42 is an allosteric agonist. Mol Pharmacol 2006; 69: 236–246
   PubMedGoogle Scholar
• Langmead C J, Christopoulos A. Allosteric agonists of 7TM receptors: Expanding the pharmacological toolbox. Trends Pharmacol Sci 2006; 27: 475–481
   PubMed Web of Science ®Google Scholar
• Sur C, Mallorga P J, et al. N-Desmethylclozapine, an allosteric agonist at the muscarinic m1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 2003; 100: 13674–13679
   PubMed Web of Science ®Google Scholar
• Spalding T, Trotter C, Skjaerbaek N, Messier T L, Currier E, Burstein E S, Li D, Hacksell U, Brann M R. Discovery of an ectopic activation site on the muscarinic m1 receptor. Mol Pharmacol 2002; 61: 1297–1302
   PubMedGoogle Scholar
• Elies R, Fu L X, Eftekhari P, Wallukat G, Schulze W, Granier C, Hjalmarson A, Hoebke J. Immunochemical and functional characterization of an agonist-like monoclonal antibody against the m2 acetylcholine receptor. Eur J Biochem 1998; 251: 659–666
   PubMedGoogle Scholar
• Jakubik J, Bacakova L, Esam V L, El-Fakahany E E, Tucek S. Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proc Natl Acad Sci U SA 1996; 93: 8705–8709
   PubMed Web of Science ®Google Scholar
• Nascimento J H, Salle J, Hoebke J, Argibay J, Peineauet N. cGMP-mediated inhibition of cardiac L-type Ca2 + current by a monoclonal antibody against the m2 Ach receptor. Am J Physiol Cell Physiol 2001; 281: C1251–C1258
   Google Scholar
• Holst B, Brandt E, Bach A, Heding A, Schwartz T W. Nonpeptide and peptide growth hormone secretagogues act as both ghrelin receptors and as positive or negative allosteric modulators of ghrelin signaling. Mol Endocrinol 2005; 19: 2400–2411
   PubMed Web of Science ®Google Scholar
• Goudet C, Gaven F, Kniazeff J, Vol C, Liu J, Cohen-Gonsaud M, Acher F, Prezeau L, Pin J P. Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proc Natl Acad Sci U SA 2004; 101: 378–383
   PubMed Web of Science ®Google Scholar
• Mitsukawa K, Yamamoto R, Ofner S, Nozulak J, Pescott O, Lukic S, Stoehr N, Mombereau C, Kuhn R, McAllister K H, van der Patten H, Cryan J F, Flor P J. A selective metabotropic glutamate receptor 7 agonist: Activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc Natl Acad Sci U SA 2005; 102: 18712–18717
   PubMed Web of Science ®Google Scholar
• Sachpatzidis A, Benton B K, et al. Identification of allosteric peptide agonists of CXCR4R. J Biol Chem 2003; 278: 896–907
   PubMed Web of Science ®Google Scholar